Selection of patients for aspirin desensitization treatment
about
Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advancesFactors driving the aspirin exacerbated respiratory disease phenotype.Interleukin-4 in the Generation of the AERD Phenotype: Implications for Molecular Mechanisms Driving Therapeutic Benefit of Aspirin Desensitization.Aspirin-exacerbated respiratory disease: evaluation and management.Aspirin hypersensitivity and desensitization protocols: implications for cardiac patientsClinical Management of Nonsteroidal Anti-inflammatory Drug Hypersensitivity.Clinical immunology review series: an approach to desensitization.Nonallergic drug hypersensitivity reactions.Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).Aspirin-exacerbated respiratory disease: characteristics and management strategies.Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations.Current complications and treatment of aspirin-exacerbated respiratory disease.Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist.Primary Cutaneous Vasculitis Masquerading as Drug Induced following Aspirin DesensitizationPlasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease.Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease.[Adaptive desensitization for acetylsalicylic acid hypersensitivity: A success story?].Samter's Triad: State of the Art.
P2860
Q26750424-B863B23D-2912-4884-B035-E34E1A980455Q30300955-A79A5D01-7279-4C96-971A-1496BC105FE6Q30428747-1615A30D-4915-47CE-AB28-B1B0DBC2C128Q30477625-FCDAD58A-E93E-4133-861D-3100A5B070D7Q33949371-AC55C567-00DD-45F5-B1DE-B089D910BD8EQ36834393-D077244A-DB7A-46D2-B2A8-2C9F216B93CDQ37822834-5A4AC7E8-EA05-49B0-A5E4-CF4A52D10E92Q38029476-C3A8723D-118E-440E-AB04-ED3B01D93ABBQ38348606-BA870BD4-4451-4BD3-99C2-A8027DEEE523Q38455960-5E004FA5-B8CE-4C83-B3CF-EDAA5225AA47Q38915358-36272E88-08FA-4D03-A9E8-A771BB92764AQ39000200-83D9CAA6-AD47-40F1-9513-49688AA7A487Q39573055-55231D0A-95CE-446E-B817-FB16A71BA011Q42233287-C1B41482-D136-4C0D-88E1-471F7C99FEB7Q47982119-76487CA2-BF34-4D0B-981D-94A4EB37A7D9Q51194137-E5828D52-053E-45F3-8CDB-DAAB7569B04AQ53341936-CEEDD2FB-77AD-44FD-BAD2-B13AE1FC1AEBQ54940852-467B7863-EF85-4984-BD3E-3D43A6C1091A
P2860
Selection of patients for aspirin desensitization treatment
description
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im Oktober 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: October 2006)
@en
vedecký článok (publikovaný 2006-10)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd in 2006-10)
@nl
наукова стаття, опублікована в жовтні 2006
@uk
مقالة علمية (نشرت في أكتوبر 2006)
@ar
name
Selection of patients for aspirin desensitization treatment
@ast
Selection of patients for aspirin desensitization treatment
@en
Selection of patients for aspirin desensitization treatment
@nl
type
label
Selection of patients for aspirin desensitization treatment
@ast
Selection of patients for aspirin desensitization treatment
@en
Selection of patients for aspirin desensitization treatment
@nl
prefLabel
Selection of patients for aspirin desensitization treatment
@ast
Selection of patients for aspirin desensitization treatment
@en
Selection of patients for aspirin desensitization treatment
@nl
P1476
Selection of patients for aspirin desensitization treatment
@en
P2093
Donald D Stevenson
Ronald A Simon
P356
10.1016/J.JACI.2006.06.019
P407
P577
2006-10-01T00:00:00Z